TBPH

9.47

1.46% -0.14

Handel nachbörslich: 9.50 0.03 +0.32%

Theravance Biopharma Inc (TBPH)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$9.61

Offen:

$9.59

24-Stunden-Volumen:

334.47K

Relative Volume:

1.76

Marktkapitalisierung:

$460.56M

Einnahmen:

$62.02M

Nettoeinkommen (Verlust:

$-45.65M

KGV:

0.8336

EPS:

11.36

Netto-Cashflow:

$-9.60M

1W Leistung:

-0.53%

1M Leistung:

+7.61%

6M Leistung:

+5.46%

1J Leistung:

-8.68%

1-Tages-Spanne:

$9.37

$9.75

1-Wochen-Bereich:

$9.37

$10.10

52-Wochen-Spanne:

$7.44

$11.71

Theravance Biopharma Inc Stock (TBPH) Company Profile

Firmenname

Theravance Biopharma Inc

Sektor

Healthcare (1195)

Branche

Biotechnology (683)

Telefon

650-808-6000

Adresse

UGLAND HOUSE, SOUTH CHURCH STREET, GEORGE TOWN, GRAND CAYMAN

Mitarbeiter

Twitter

Nächster Verdiensttermin

2024-11-12

Neueste SEC-Einreichungen

TBPH's Discussions on Twitter

Vergleichen Sie TBPH mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
TBPH	9.47	460.56M	62.02M	-45.65M	-9.60M	11.36
VRTX	450.97	116.14B	10.63B	-479.80M	-1.35B	13.33
REGN	738.00	81.10B	13.85B	4.65B	3.32B	35.06
ARGX	605.92	36.23B	1.86B	-40.29M	-1.28B	-4.16
ALNY	244.89	31.59B	2.09B	-332.26M	16.06M	-4.14
BNTX	113.13	27.12B	3.30B	-501.07M	1.03B	11.54

Theravance Biopharma Inc Stock (TBPH) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2022-05-23	Eingeleitet	SVB Leerink	Outperform
2021-11-05	Hochstufung	JP Morgan	Underweight → Neutral
2021-09-15	Herabstufung	JP Morgan	Overweight → Underweight
2021-08-25	Herabstufung	Morgan Stanley	Overweight → Underweight
2021-08-24	Herabstufung	Cowen	Outperform → Market Perform
2020-10-14	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2020-07-07	Eingeleitet	JP Morgan	Overweight
2020-06-15	Eingeleitet	Morgan Stanley	Equal-Weight
2020-05-13	Eingeleitet	Cowen	Outperform
2020-01-08	Bestätigt	H.C. Wainwright	Buy
2019-11-06	Hochstufung	Robert W. Baird	Underperform → Neutral
2019-10-29	Eingeleitet	H.C. Wainwright	Buy
2018-03-29	Fortgesetzt	Piper Jaffray	Overweight
2017-08-17	Eingeleitet	Evercore ISI	Outperform
2017-06-16	Eingeleitet	Cantor Fitzgerald	Overweight
2017-05-11	Bestätigt	Needham	Buy
2016-12-21	Eingeleitet	Needham	Buy
2016-11-03	Eingeleitet	Piper Jaffray	Overweight
2016-10-12	Herabstufung	Robert W. Baird	Neutral → Underperform
2016-08-03	Herabstufung	BofA/Merrill	Neutral → Underperform
2016-06-20	Eingeleitet	Guggenheim	Buy
2016-06-20	Bestätigt	Leerink Partners	Outperform
2016-05-12	Eingeleitet	Leerink Partners	Outperform
2016-05-05	Herabstufung	BofA/Merrill	Buy → Neutral
2015-02-03	Hochstufung	Robert W. Baird	Underperform → Neutral

Alle ansehen

Theravance Biopharma Inc Aktie (TBPH) Neueste Nachrichten

Nov 21, 2024

Theravance's Q3 Loss Narrower Than Expected, Revenues Rise Y/Y - MSN

Nov 21, 2024

Nov 20, 2024

Multiple System Atrophy Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | Ionis Pharma, Biohaven Pharma, Lundbeck A/S, Alterity Therapeutics, Theravance Biopharma - The Globe and Mail

Nov 20, 2024

Theravance Biopharma to Present at Evercore HealthCONx Conference | TBPH Stock News - StockTitan

Nov 20, 2024

Madison Avenue Partners, LP Expands Stake in Theravance Biopharm - GuruFocus.com

Nov 14, 2024

Theravance Biopharma Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance

Nov 14, 2024

Analysts Set Theravance Biopharma, Inc. (NASDAQ:TBPH) PT at $13.75 - MarketBeat

Nov 14, 2024

Nov 13, 2024

Theravance Biopharma SVP Rhonda Farnum sells $36,000 in shares - Investing.com India

Nov 13, 2024

Theravance Biopharma SVP Rhonda Farnum sells $36,000 in shares By Investing.com - Investing.com Canada

Nov 13, 2024

Theravance Biopharma, Inc. (NASDAQ:TBPH) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 13, 2024

Theravance Biopharma (NASDAQ:TBPH) Stock Price Crosses Above Fifty Day Moving AverageTime to Sell? - MarketBeat

Nov 13, 2024